Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1032 | Control (standard clinical practice) Wiki | 1.00 |
| drug4507 | hospitalized children with Covid19 Wiki | 1.00 |
| drug2717 | Optimal-Massive Intervention Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003681 | Dehydration NIH | 1.00 |
| D009059 | Mouth Diseases NIH | 0.58 |
| D044342 | Malnutrition NIH | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0004395 | Malnutrition HPO | 0.50 |
| HP:0002015 | Dysphagia HPO | 0.41 |
| HP:0011947 | Respiratory tract infection HPO | 0.16 |
Navigate: Correlations HPO
There is one clinical trial.
The aim of this study is to evaluate the efficacy of an optimal-massive intervention (OMI) based on increasing shear viscosity of fluids, nutritional support with oral nutritional supplements (ONS) and triple adaptation of food (rheological and textural, caloric and protein and organoleptic) and oral hygiene improvement on the incidence of respiratory infections in older patients with OD. We have designed a randomized clinical trial, with two parallel arms and 6 months follow-up. The study population will be constituted by older patients of 70 years or more with OD hospitalized at Hospital de Mataró by an acute process that will be identified by using the volume-viscosity swallow clinical test. We will consecutively recruit 500 subjects during admission (Geriatrics, Internal medicine, etc.) at the Hospital de Mataró. Patients included will be randomly assigned to one of both interventional groups: a) study intervention: multifactorial intervention based on fluid viscosity adaptation (with a xanthan gum thickener -> Nutilis Clear®), nutritional support with a triple adaptation of food (texture, caloric and protein content, organoleptic) + pre-thickened ONS and evaluation and treatment of oral hygiene (tooth brushing + antiseptic mouthwashes + professional dental cleaning), or b) control intervention: standard clinical practice (fluid adaptation with Nutilis Powder and simple texture adaptation for solids). Main outcome measures: respiratory infection incidence during the 6-month period follow-up. Secondary outcomes: mortality at 6 months, general hospital readmissions and readmissions due to respiratory infections, nutritional status, hydration status, quality of life, functional status, oral hygiene and dysphagia severity and its relationship with other study variables.
Description: Respiratory infections incidence (includes LRTI, pneumonia and exacerbations of COPD): all new episodes of respiratory infections recorded in the clinical history or in the reports presented by the patient will be recorded. LRTI: presence of at least 2 of the following symptoms without other cause to explain them: fever, cough, purulent expectoration, rhonchi or wheezing. Pneumonia: performing 1 or more radiographic tests with new condensation, fever or leukopenia or leukocytosis and at least: cough, purulent expectoration, dyspnea, tachypnea, suggestive auscultation or worsening of gas exchange. COPD exacerbation: acute exacerbation of COPD is a sudden worsening of COPD symptoms (shortness of breath, quantity and color of phlegm) that typically lasts for several days. It may be triggered by an infection with bacteria or viruses or by environmental pollutants.
Measure: Respiratory infections incidence. Time: From discharge to 6 months follow-upDescription: Mortality: the date and reason for death will be recorded (hospitalization, 1, 3 and 6 months).
Measure: Mortality Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: General readmissions and readmissions for respiratory infections (1, 3 and 6 months): LRTI, pneumonia and exacerbations of COPD: the reason for admission will be that stated in the hospital database (CMBDAH) according to CIM-10. The information source of the readmissions will be the registration of hospital discharges that is integrated into the hospital information system and that includes the CIM-10 codes of the main and secondary diagnoses of the episode that caused the admission, the date of admission and discharge and the days of hospitalization. Readmissions from pneumonia (codes CIM-10): J13, J18.1, J15.1, J14, J15.4, J15.211, J15.5, A48.1, J15.8, J18.0, J18.8, J69.0; readmissions for LRTI (no pneumonic): J20.0 - J20.9, J10.1, J11.1, J41.8, J44.1 and J44.0. Readmissions from exacerbation of COPD: J441.
Measure: General readmissions and readmissions for respiratory infections Time: Through study completion, at 1, 3 and 6 months from disharge.Description: Mini-nutritional assessment form (MNA) (hospitalization, 1, 3 and 6 months).
Measure: Nutritional status (MNA) Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Heigh in cm (hospitalization, 1, 3 and 6 months).
Measure: Nutritional status (Anthropometric measures) Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Weight in kg (hospitalization, 1, 3 and 6 months).
Measure: Nutritional status (Anthropometric measures2) Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Biochemical parameters from blood analysis (hospitalization, 3 and 6 months).
Measure: Nutritional status (Biochemical parameters) Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Hydration status: we will register total body water and intracellular water with bioimpedance (hospitalization, 1, 3 and 6 months).
Measure: Hydration status (bioimpedance) Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Quality of life: EQ-5D questionnaire will be used (hospitalization, 1, 3 and 6 months).
Measure: Quality of life of patients during the study period Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Functional status: we will use the Barthel Index (hospitalization, 1, 3 and 6 months).
Measure: Functional status Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Oral Hygiene: the OHI-S (simplified oroal hygiene index) will be collected (hospitalization, 1, 3 and 6 months).
Measure: Oral Hygiene Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Severity of dysphagia: according to the different viscosities that patients will be able to swallow and with the Functional Oral Intake Scale (V-VST/FOIS) (hospitalization, 1, 3 and 6 months).
Measure: Dysphagia severity Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Sociodemographic characteristics of the study population.
Measure: Sociodemographics Time: BaselineDescription: Swallowing function (V-VST) (hospitalization, 1, 3 and 6 months).
Measure: Swallowing function (V-VST) Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Rate of institutionalization (1, 3 and 6 months).
Measure: Institutionalization Time: Through study completion, at 1, 3 and 6 months from disharge.Description: Drugs taken by the patient.
Measure: Pharmacological treatment Time: BaselineDescription: Geriatric syndromes
Measure: Geriatric syndromes Time: BaselineDescription: Fried criteria (hospitalization, 1, 3 and 6 months).
Measure: Frailty 1 Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Edmonton frail scale (hospitalization, 1, 3 and 6 months).
Measure: Frailty 2 Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Smoking and alcohol consumption
Measure: Toxic habits Time: BaselineDescription: Compliance with the recommendations of the study intervention (adaptations of fluid, prescribed diets and oral hygiene) (hospitalization, 1, 3 and 6 months).
Measure: Compliance Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Palatability of the intervention products will be measured with the 5-point facial hedonic scale (hospitalization, 1, 3 and 6 months).
Measure: Palatability Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Description: Acceptability of the dietes will be measured with the Food Action Rating Scale (hospitalization, 1, 3 and 6 months)
Measure: Acceptability Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports